Our cell reprogramming technology is based on a set of core molecular pathways that influence cell differentiation. Our primary means of reprogramming is our unique sets of chemical cocktails, but sometimes combined with other non-integrative methods to ensure repeatability and stability. We believe that cells of early development stage or young cells of fully differentiated cells have may also have clinical utility, not the embryonic stem cells themselves. Our technology allows us to manipulate the development stages of cells, thereby, enhancing our potential to meet various clinical needs. Also, the culture media that we obtain through cell reprogramming tends to be functionally specific to the particular organ regeneration for which we grow cells.